New bone drug goes Head-to-Head with market leader

NCT ID NCT05345691

Summary

This study tested whether a new osteoporosis drug called Bmab 1000 works as well as the established medication Prolia. Researchers enrolled 479 postmenopausal women with osteoporosis and randomly assigned them to receive either the new drug or Prolia via injection every six months. The main goal was to see if both treatments improved bone mineral density to a similar degree over one year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • PPD Global Ltd, Granta Park, Great Abington,

    Cambridge, UK, CB21 6GQ, United Kingdom

Conditions

Explore the condition pages connected to this study.